COVID-19 Delays Phase 3 Trial of Givinostat in DMD, Italfarmaco Says in Webinar
Because of the global COVID-19 pandemic, Italfarmaco has paused enrollment of boys with Duchenne muscular dystrophy (DMD) in a Phase 3 trial of its investigational treatment givinostat, the company said in a recent webinar hosted by Parent Project Muscular Dystrophy. Although treatment of current…